The Industrial Participant Program (IPP) serves as a collaboration hub for the industry-facing component of the Wyss Diagnostics Accelerator. Meet our members, ranging from early stage startups to multinational corporations.
Wyss Diagnostics Accelerator (DxA)
An initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs
Want to learn more?
Please get in touch if you are interested in learning more about the Wyss DxA, submitting information about unmet clinical diagnostic needs, or joining the pilot phase of our Industrial Participant Program.
Program Leads
Industrial Participants
Clinical Collaborator
Want to learn more?
Please get in touch if you are interested in learning more about the Wyss DxA, submitting information about unmet clinical diagnostic needs, or joining the pilot phase of our Industrial Participant Program.
Our Mission
To ultimately save lives by accelerating the development and deployment of needed diagnostics, the Wyss Diagnostics Accelerator (DxA) formed as a multifaceted collaboration between clinicians, researchers, engineers, funding agencies, philanthropists, government agencies, and industry partners. These partners work together to:
- Identify unmet diagnostic needs
- Fund technology research and development
- Conduct clinical studies
- Work with regulators, payers, NGOs, and industry to advance commercialization efforts of the most promising technologies
- Ultimately measure successful outcomes in all settings, particularly with underserved populations
Bench to Bedside: Clinical Collaboration
Our acceleration process begins with clinicians who identify critical unmet medical diagnostic needs. They then work alongside Wyss scientists and engineers to help develop technologies to address these specific problems. As promising technologies are developed in Wyss labs, they are brought to the CLIA-certified lab at the Brigham and Women’s Hospital to be tested with real patient samples. The CLIA designation is granted by the FDA and sets clinical standards for clinical laboratory testing performed on human samples, which means these Wyss-developed technologies are being used under similar standards that the FDA uses when evaluating products for approval in the market. The Wyss teams then use clinician feedback to further refine and enhance these technologies before bringing them back to the CLIA lab.
We want to make a paradigm shift – Most new diagnostics are developed through a ‘technology push.’ We want to pull technology to solve clinical problems.
Industrial Participant Program
Developing a new diagnostic that tests well in the lab is not enough – these tools need to work well at scale and in the market. The Wyss DxA Industrial Participant Program (IPP) serves as a collaboration hub between healthcare testing companies, and the scientific and clinical community within the Wyss Institute, as well as our affiliated institutions and the broader Harvard ecosystem.
Participants build relationships and explore pre-competitive collaboration opportunities, connect with thought leaders and subject matter experts, identify key opportunities and challenges within the industry, and align on a vision to transform the future of diagnostic and healthcare testing, all driven by the passion to solve unmet diagnostic needs.
Wyss DxA IPP
Meet Our Industrial Participants
The Industrial Participant Program (IPP) is the industry-facing component of the Wyss Diagnostics Accelerator. Learn more about our current program participants.
All industry participants are 100% aligned with our vision which we hope, in the longer term, will help build a broad coalition of diagnostic stakeholders to drive innovation, facilitate new partnerships and identify emerging technologies and associated opportunities.
Want to learn more?
Please get in touch if you are interested in learning more about the Wyss DxA, submitting information about unmet clinical diagnostic needs, or joining the pilot phase of our Industrial Participant Program.